IFN-ß-1a (Rebif®) ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00391352 (ClinicalTrials.gov)	February 2008	19/10/2006	fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls	A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-ß-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.	Relapsing-Remitting Multiple Sclerosis	Drug: IFN-ß-1a (Rebif®)	Waukesha Memorial Hospital	The Cleveland Clinic	Completed	18 Years	65 Years	Both	21	Phase 4	United States